Medtronic and Qualcomm has signed a global, multi-year collaboration to jointly develop future generation continuous glucose monitoring (CGM) systems that aim to improve health outcomes for people with diabetes. Both companies want to enable more informed care, by giving insights to doctors and people with type 2 diabetes concerning glucose levels specifically for those who do not have control of their diabetes today.
The initial focus of the collaboration would be to develop a single-use CGM system designed for broader practice by general practitioners who manage care for the vast majority of the 400 million people worldwide with type 2 diabetes.
This collaboration supports Medtronic’s strategy to develop comprehensive CGM solutions that not only measure glucose but enable the delivery of actionable insights to both patients and providers.
Leveraging Qualcomm Life’s deep wireless expertise and technologies, 2net(TM) Design is a platform for designing the communications components of connected medical devices, including disposable drug delivery devices and disposable diagnostic devices for condition specific connected therapies.
“We believe that glucose should be a vital sign of diabetes health. Professional CGM is an increasingly used diagnostic tool that empowers physicians and patients with meaningful glucose data to tackle glucose control. Our solutions go beyond delivering data and provide automated observations and clinical decision support to help create a personalized care plan,” said Laura Stoltenberg, vice president and general manager, Non-Intensive Diabetes Therapies at Medtronic. “Our vision is to transform diabetes care so people with diabetes can enjoy greater freedom and better health. We are thrilled to be collaborating with Qualcomm Life – a best-in-class leader in wireless technologies that is ahead of the curve in a rapidly changing connected world – to develop innovative and affordable CGM systems that will fundamentally change type 2 diabetes management.”